Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | KAT7 | O95251 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 10/20 | 0.38 |
| ▸ | CA2 | P00918 | 10/20 | 0.38 |
| ▸ | CA4 | P22748 | 10/20 | 0.38 |
| ▸ | CA9 | Q16790 | 10/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494284 | 0.92 | NR1H2 (0.46) | NR1H2NR1H3ABHD6DAGLADPP4 | |
| SCHEMBL3494805 | 0.91 | NR1H2 (0.46) | NR1H2NR1H3ABHD6DAGLADPP4 | |
| SCHEMBL5141229 | 0.90 | CA1 (0.42) | NR1H2NR1H3CA1CA2CA4 | |
| SCHEMBL8237503 | 0.89 | NR1H2 (0.46) | NR1H2NR1H3ABHD6DAGLADPP4 | |
| SCHEMBL13340386 | 0.89 | NR1H2 (0.44) | NR1H2NR1H3ABHD6DAGLADPP4 | |
| SCHEMBL8238325 | 0.89 | NR1H2 (0.44) | NR1H2NR1H3ABHD6DAGLADPP4 | |
| SCHEMBL3496189 | 0.88 | NR1H2 (0.46) | NR1H2NR1H3ABHD6DAGLADPP4 | |
| SCHEMBL8237620 | 0.88 | NR1H2 (0.46) | NR1H2NR1H3ABHD6DAGLADPP4 | |
| SCHEMBL8235365 | 0.88 | NR1H2 (0.44) | NR1H2NR1H3ABHD6DAGLADPP4 | |
| SCHEMBL13340440 | 0.88 | NR1H2 (0.43) | NR1H2NR1H3ABHD6DAGLADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | NR1H2 339/4885NR1H3 293/4885ABHD6 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.